Bioequivalence of Cyclosporine A 100 mg Soft Capsules (Cipol-N® vs. Sandimmun Neoral®) in Healthy Korean Volunteers |
Huh, Yong-Ho
(Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology)
Park, Eun-A (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) Chung, Youn-Bok (College of Pharmacy, Chungbuk National University) Pyo, Hee-Soo (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) Kwon, Oh-Seung (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) |
1 | EC, European Community, Investigation of Bioavailability and Bioequivalence, The Rules Governing Medicinal Products in European Community, Vol. III, 149-169, Addendum 2 (1991) |
2 | KFDA, K-BE test for Window, Lee YJ, Chung SJ, and Shim CK, Version 1.2.1 (2002) |
3 | KFDA, Guidance for Industry. Statistical Approaches to Establishing Bioequivalence, Bioequivalence Division, Pharmacology Department, National Institute of Toxicology Department, http://www.kfda.go.kr (2005) |
4 | FDA, Guidance for Industry. Statistical Approaches to Establishing Bioequivalence, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and research (CDER). Office of Training and Communication, Division of Communications Management, Rockville, MD (January 2001) |
5 | KFDA, Notification No. 2005-31, The Standard Protocol of Bioequivalence Test (June 07, 2005) |
6 | White DJ, Plumb AM, Pawelec G and Brons G, Cyclosporine A, an immunosuppressive agent preferentially active against proliferating T cells, Transplantation, 27, 55-58 (1979) DOI ScienceOn |
7 | Min DI, Lee M, Ru YM and Flanigan M, Gender-dependent racial difference in disposition of cyclosporine among healthy African, African American and White volunteers. Clin. Pharmacol. Ther., 68, 478- (2000) DOI ScienceOn |
8 | Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB and Wood AJJ, Cyclosporine pharmacokinetics and pharmacodynamics in African American and White subjects, Clin. Pharmacol. Ther., 69, 317- (2001) DOI ScienceOn |
9 | KFDA, 18. Cyclosporine, In "The Standard Protocols of Bioequivalence Tests", 94-98 (2002) |
10 | Brozmanova B., Grundmann M, Safarcik K and Jegorov A, High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients, J. Chromatogr. B., 749, 93-100 (2000) DOI ScienceOn |
11 | Fowler MB and Schroeder JS, Current status of cardiac transplantation, Mod. Concepts Cardiovasc. Dis., 55, 37-41 (1986) |
12 | Garcia-Escriq M, Martinez J, Fernandez-Ponsati J, Diaz J and Soto O, Severe central nervous system toxicity after chronic treatment with cyclosporine, Clin. Neuropharmacol., 17, 298-302 (1994) |
13 | Kahan BD, Mickey R, Flechner SM, Lorber MI, Wideman CA, Kerman RH, Tersaki P and van Buren CT, Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients, Transplantation, 43, 65-70 (1987) DOI ScienceOn |
14 | Magnasco A, Rossi A, Cartasi P, Gusmano R, Ginevri F, Perfumo F and Ghiggeri GM, Cyclosporine and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives, Curr. Clin. Pharamcol., 3, 166-173 (2008) DOI |
15 | O'Grady JG, Forbes A, Rolles K, Calne RY and William R, An analysis of cyclosporine efficacy and toxicity after liver transplantation, Transplantation, 45, 575-579 (1988) DOI ScienceOn |
16 | Kronbach T, Fischer V and Mever UA, Cyclosporine metabolism in human liver: identification of cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interaction of cyclosporine with other drugs, Clin. Pharmacol. Ther., 43, 630-635 (1988) DOI ScienceOn |